NESS ZIONA, Israel, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that management will participate in the Jefferies 2018 London Healthcare Conference. 

The Jefferies 2018 London Healthcare Conference is being held on November 14-15, 2018. Dr. Alon Seri-Levy, Chief Executive Officer, and Gilad Mamlok, Chief Financial Officer, will provide a business overview and update on the company’s pipeline programs on Wednesday, November 14^th at 8:40 a.m. GMT.

A live audio webcast of the presentation will be available in the Investors/Events & Presentations section of the Sol-Gel Technologies website at http://www.sol-gel.com/. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days. 

About Sol-Gel Technologies

Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel’s current product candidate pipeline consists of late-stage branded product candidates that leverage our proprietary, silica-based microencapsulation technology platform, and several generic product candidates across multiple indications. For additional information, please visit www.sol-gel.com.

For further information, please contact:

Sol-Gel Contact:
Gilad Mamlok
Chief Financial Officer
+972-8-9313433

Investor Contact:
Patricia L. Bank
Westwicke Partners
+1-415-513-1284
patti.bank@westwicke.com